Division of Nephrology, Hospital for Sick Children, Toronto, Ontario, Canada.
J Am Soc Nephrol. 2013 Jul;24(8):1274-87. doi: 10.1681/ASN.2012090890. Epub 2013 Jun 13.
Neutrophils recruited to the postischemic kidney contribute to the pathogenesis of ischemia-reperfusion injury (IRI), which is the most common cause of renal failure among hospitalized patients. The Slit family of secreted proteins inhibits chemotaxis of leukocytes by preventing activation of Rho-family GTPases, suggesting that members of this family might modulate the recruitment of neutrophils and the resulting IRI. Here, in static and microfluidic shear assays, Slit2 inhibited multiple steps required for the infiltration of neutrophils into tissue. Specifically, Slit2 blocked the capture and firm adhesion of human neutrophils to inflamed vascular endothelial barriers as well as their subsequent transmigration. To examine whether these observations were relevant to renal IRI, we administered Slit2 to mice before bilateral clamping of the renal pedicles. Assessed at 18 hours after reperfusion, Slit2 significantly inhibited renal tubular necrosis, neutrophil and macrophage infiltration, and rise in plasma creatinine. In vitro, Slit2 did not impair the protective functions of neutrophils, including phagocytosis and superoxide production, and did not inhibit neutrophils from killing the extracellular pathogen Staphylococcus aureus. In vivo, administration of Slit2 did not attenuate neutrophil recruitment or bacterial clearance in mice with ascending Escherichia coli urinary tract infections and did not increase the bacterial load in the livers of mice infected with the intracellular pathogen Listeria monocytogenes. Collectively, these results suggest that Slit2 may hold promise as a strategy to combat renal IRI without compromising the protective innate immune response.
中性粒细胞被招募到缺血性肾脏中,有助于缺血再灌注损伤(IRI)的发病机制,这是住院患者中肾衰竭的最常见原因。Slit 家族分泌的蛋白通过阻止 Rho 家族 GTP 酶的激活来抑制白细胞的趋化作用,这表明该家族的成员可能调节中性粒细胞的募集和由此产生的 IRI。在这里,在静态和微流控剪切测定中,Slit2 抑制了中性粒细胞浸润组织所需的多个步骤。具体来说,Slit2 阻断了人中性粒细胞与炎症血管内皮屏障的捕获和牢固粘附,以及随后的迁移。为了研究这些观察结果是否与肾 IRI 相关,我们在双侧肾蒂夹闭前向小鼠施用 Slit2。在再灌注后 18 小时评估时,Slit2 显著抑制肾小管坏死、中性粒细胞和巨噬细胞浸润以及血浆肌酐升高。在体外,Slit2 不会损害中性粒细胞的保护功能,包括吞噬作用和超氧化物产生,也不会抑制中性粒细胞杀死细胞外病原体金黄色葡萄球菌。在体内,Slit2 的给药不会减弱患有上行性大肠埃希菌尿路感染的小鼠中性粒细胞的募集或细菌清除,也不会增加感染细胞内病原体单核细胞增生李斯特菌的小鼠肝脏中的细菌负荷。总的来说,这些结果表明,Slit2 可能有希望作为一种治疗肾 IRI 的策略,而不会损害保护性先天免疫反应。